SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.

Siegel, Corey A.; Melmed, Gil Y.; McGovern, Dermot Pb; Rai, Victoria; Krammer, Florian; Rubin, David T.; Abreu, Maria T.; Dubinsky, Marla C.

doi:10.1136/gutjnl-2020-324000

Article (Scientific journals)

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.

Siegel, Corey A.; Melmed, Gil Y.; McGovern, Dermot Pb et al.

2021 • In Gut, 70 (4), p. 635-640

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/266131

DOI
10.1136/gutjnl-2020-324000

PubMed
33472895

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

SARS-CoV-2 vaccination for patients with IBD recommendations from an international consensus meeting_Gut_PPE.pdf

Publisher postprint (3.37 MB)

Download

Copyright information: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Anti-Inflammatory Agents/immunology/pharmacology; COVID-19/epidemiology/immunology/prevention & control; COVID-19 Vaccines/classification/immunology/therapeutic use; Consensus; Gastroenterology/methods/standards; Humans; Immunogenicity, Vaccine/drug effects/immunology; Immunomodulation/drug effects/immunology; Inflammatory Bowel Diseases/drug therapy/immunology; International Cooperation; SARS-CoV-2; Vaccination/methods/standards; COVID-19; IBD; crohn's disease; immune response; ulcerative colitis

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Siegel, Corey A.

Melmed, Gil Y.

McGovern, Dermot Pb

Rai, Victoria

Krammer, Florian

Rubin, David T.

Abreu, Maria T.

Dubinsky, Marla C.

Other collaborator :

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Language :

English

Title :

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.

Publication date :

2021

Journal title :

Gut

ISSN :

0017-5749

eISSN :

1468-3288

Publisher :

BMJ Publishing Group, United Kingdom

Volume :

Issue :

Pages :

635-640

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://dx.doi.org/10.1136/gutjnl-2020-324000

Available on ORBi :

since 15 December 2021

Statistics

Number of views

83 (2 by ULiège)

Number of downloads

82 (1 by ULiège)

More statistics

Scopus citations^®

154

Scopus citations^®
without self-citations

146

OpenCitations

137

Bibliography

Available: https://coronavirus.jhu.edu/map.html [Accessed on December 20, 2020].
Wrapp D, Wang N, Corbett KS, et al. Cryo-Em structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260-3.
Wrapp D, De Vlieger D, Corbett KS, et al. Structural basis for potent neutralization of Betacoronaviruses by single-domain camelid antibodies. Cell 2020;181:1004-15.
Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020;586:567-71.
Krammer F. SARS-CoV-2 vaccines in development. Nature 2020;586:516-27.
Persad G, Peek ME, Emanuel EJ. Fairly prioritizing groups for access to COVID-19 vaccines. JAMA 2020. doi:10.1001/jama.2020.18513. [Epub ahead of print: 10 Sep 2020].
Available: https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html [Accessed on May 9, 2020].
Available: https://apps.who.int/iris/bitstream/handle/10665/334299/WHO-2019-nCoV-SAGE-Framework-Allocation-and-prioritization-2020.1-eng.pdf [Accessed December 20, 2020].
Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:148-54.
deBruyn JCC, Hilsden R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:25-33.
Andrisani G, Frasca D, Romero M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-αagents: effects of combined therapy with immunosuppressants. J Crohns Colitis 2013;7:301-7.
Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2012;18:1042-7.
Farraye FA, Melmed GY, Lichtenstein GR, et al. Acg clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 2017;112:241-58.
Manser CN, Maillard MH, Rogler G, et al. Vaccination in patients with inflammatory bowel diseases. Digestion 2020;101:58-68.
Lopez A, Mariette X, Bachelez H, et al. Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. J Autoimmun 2017;80:10-27.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-15.
Rubin DT, Abreu MT, Rai V, et al. International Organization for the Study of Inflammatory Bowel D. Management of Patients with Crohn's Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting. Gastroenterology 2020.
Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND/UCLA Appropriateness Method User's Manual. Santa Monica, California: RAND, 2001.
Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical Guideline development. Health Technol Assess 1998;2:1-88.
Benchimol EI, Tse F, Carroll M, et al. 124 Canadian association of gastroenterology clinical practice guidelines on immunizations in inflammatory bowel disease. Gastroenterology 2020;158:S-23.
deBruyn J, Fonseca K, Ghosh S, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis 2016;22:638-47.
Rahier J-F, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011;60:456-62.
Pineton de Chambrun G, Dauchet L, Gower-Rousseau C, et al. Vaccination and risk for developing inflammatory bowel disease: a meta-analysis of case-control and cohort studies. Clin Gastroenterol Hepatol 2015;13:1405-15. quiz e130.
Ungaro RC, Brenner EJ, Gearry RB. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021;70:725-32.
Singh AK, Jena A, Kumar-M P, et al. Risk and outcomes of coronavirus disease (COVID-19) in patients with inflammatory bowel disease: a systematic review and meta-analysis. United European Gastroenterol J 2020:205064062097260.
D'Amico F, Danese S, Peyrin-Biroulet L. Systematic review on inflammatory bowel disease patients with coronavirus disease 2019: it is time to take stock. Clin Gastroenterol Hepatol 2020;18:2689-700.
Available: https://www.rcog.org.uk/en/news/covid-19-vaccination-and-pregnancy/ [Accessed December 20, 2020].
Available: https://www.acog.org/clinical/clinicalguidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-againstcovid-19 [Accessed December 20, 2020].
Available: https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-2-december-2020/priority-groups-for-coronavirus-covid-19-vaccinationadvice-from-the-jcvi-2-december-2020 [Accessed December 16, 2020].
Available: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html [Accessed December 16, 2020].
Jeyanathan M, Afkhami S, Smaill F, et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 2020;20:615-32.
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.
Melmed GY, Rubin DT, McGovern DPB. Winter is coming! clinical, immunologic, and practical considerations for vaccinating patients with inflammatory bowel disease during the coronavirus Disease-2019 pandemic. Gastroenterology 2020. doi:10.1053/j.gastro.2020.10.013. [Epub ahead of print: 14 Oct 2020].
Available: https://investors.modernatx.com/newsreleases/news-release-details/moderna-announcesprimary-efficacy-analysis-phase-3-cove-study [Accessed on December 29, 2020].
Pratt PK, David N, Weber HC, et al. Antibody response to hepatitis B virus vaccine is impaired in patients with inflammatory bowel disease on infliximab therapy. Inflamm Bowel Dis 2018;24:380-6.
Agarwal N, Ollington K, Kaneshiro M, et al. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine 2012;30:1413-24.
Caldera F, Hillman L, Saha S, et al. Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial. Inflamm Bowel Dis 2020;26:593-602.
Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 2016;75:687-95.
Doornekamp L, Goetgebuer RL, Schmitz KS, et al. High Immunogenicity to Influenza Vaccination in Crohn's Disease Patients Treated with Ustekinumab. Vaccines 2020;8.
Brodmerkel C, Wadman E, Langley RG, et al. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol 2013;12:1122-9.
Haykir Solay A, Eser F. High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study. Hum Vaccin Immunother 2019;15:1177-82.
Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut 2015;64:77-83.
Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012;30:1210-6.
Sariol A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity 2020;53:248-63.
Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol 2010;84:9318-25.
Ni L, Ye F, Cheng M-L, et al. Detection of SARS-CoV-2-Specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 2020;52:971-7.